Serono boosted by EU decision

Serono saw its shares in demand on Wednesday following the European Union's decision to grant it 10-year exclusive marketing rights in Europe for its AIDS drug, Serostim.

This content was published on September 13, 2000 - 13:08

The exclusivity arrangement, known as orphan status, is a new EU policy that came into effect at the beginning of the year. Its aim is to encourage the development of drugs that treat rare diseases.

Serostim is used to treat AIDS-related weight loss, a condition that is suffered by up to 30 per cent of AIDS patients.

The drug is already on the market in the United States, Japan, Hong Kong and some Latin American countries.

swissinfo with agencies

Articles in this story

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Sort by

Change your password

Do you really want to delete your profile?

Your subscription could not be saved. Please try again.
Almost finished... We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.

Discover our weekly must-reads for free!

Sign up to get our top stories straight into your mailbox.

The SBC Privacy Policy provides additional information on how your data is processed.